171 related articles for article (PubMed ID: 8793400)
1. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients.
Denton M; Todd NJ; Littlewood JM
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):402-5. PubMed ID: 8793400
[TBL] [Abstract][Full Text] [Related]
2. Oral anti-pseudomonal antibiotics for cystic fibrosis.
Remmington T; Jahnke N; Harkensee C
Cochrane Database Syst Rev; 2007 Jul; (3):CD005405. PubMed ID: 17636796
[TBL] [Abstract][Full Text] [Related]
3. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
McKnight AJ; Shaw A; Goldsmith CE; Clarke L; Millar BC; McCaughan J; Elborn JS; Reid A; Moore JE
Br J Biomed Sci; 2005; 62(1):30-2. PubMed ID: 15816210
[No Abstract] [Full Text] [Related]
4. Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis.
Bauernfeind A; Emminger G; Hörl G; Ott S; Przyklenk B; Weisslein-Pfister C
Infection; 1987; 15(5):403-6. PubMed ID: 3121519
[TBL] [Abstract][Full Text] [Related]
5. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
Banerjee D; Stableforth D
Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas colonization in cystic fibrosis. A study of 160 patients.
Kulczycki LL; Murphy TM; Bellanti JA
JAMA; 1978 Jul; 240(1):30-4. PubMed ID: 96277
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of Stenotrophomonas maltophilia bacteremia in children.
Furuichi M; Ito K; Miyairi I
Pediatr Int; 2016 Feb; 58(2):113-8. PubMed ID: 26139084
[TBL] [Abstract][Full Text] [Related]
8. [Antibiotic therapy of cystic fibrosis in children].
Kapranov NI; Shabalova LA; Kashirskaia NIu; SimonovaO OI; Voronkova AIu; Osipova IA; Semykin SIu; Polikarpova SV; Postnikov SS
Antibiot Khimioter; 2001; 46(2):26-32. PubMed ID: 11544748
[TBL] [Abstract][Full Text] [Related]
9. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
Millar BC; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
[TBL] [Abstract][Full Text] [Related]
10. Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis.
Lim SZP; Fitzgerald DA
Paediatr Respir Rev; 2018 Jun; 27():33-36. PubMed ID: 29033215
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
Mathy V; Grohs P; Compain F
J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
[TBL] [Abstract][Full Text] [Related]
12. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN
Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118
[TBL] [Abstract][Full Text] [Related]
13. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
[TBL] [Abstract][Full Text] [Related]
14. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.
Zobell JT; Young DC; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Jun; 48(6):525-37. PubMed ID: 23359557
[TBL] [Abstract][Full Text] [Related]
15. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
Rutter WC; Burgess DR; Burgess DS
Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
[TBL] [Abstract][Full Text] [Related]
17. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
Nazik H; Ongen B; Erturan Z; Salcioğlu M
Jpn J Infect Dis; 2007 May; 60(2-3):82-6. PubMed ID: 17515637
[TBL] [Abstract][Full Text] [Related]
18. Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm.
Lutz L; Pereira DC; Paiva RM; Zavascki AP; Barth AL
BMC Microbiol; 2012 Sep; 12():196. PubMed ID: 22958421
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients.
VanDevanter DR; Van Dalfsen JM; Burns JL; Mayer-Hamblett N
J Pediatric Infect Dis Soc; 2015 Jun; 4(2):151-4. PubMed ID: 26407415
[TBL] [Abstract][Full Text] [Related]
20. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
